Southeast Asia RNAi Technology Market: Current Analysis and Forecast (2025-2033)

Southeast Asia RNAi Technology Market Size & Forecast

The Southeast Asia RNAi Technology Market was valued at ~USD 80.20 million in 2024 and is expected to grow at a strong CAGR of approximately 16.25% during the forecast period (2025-2033F), driven by the adoption of RNAi tools in genomics, molecular biology, and early-stage drug discovery.

Southeast Asia RNAi Technology Market Analysis

RNAi technology is a gene-silencing technology that allows the specific regulation of the activity of genes with the help of short interfering RNAs or other similar molecules. It is widely used in biomedical research, drug discovery, and targeted therapeutics development.

To achieve growth in Southeast Asia, RNAi is being adopted in research and discovery processes due to government subsidies, academic-industrial partnerships, the need to shorten drug development cycles, and coherent research and development. Also, advances in RNA delivery technologies and increased validation in gene-silencing therapeutics are driving long-term commercial interest in the field. The increasing use of RNAi in rare disease, oncological, and metabolic disorder research is also observed in Southeast Asia, supported by emerging lab infrastructure and outsourcing models.

On December 2, 2025, Thermo Fisher Scientific Inc., the world leader in serving science, announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and expanding its existing Bioprocess Design Centers in Incheon, Korea, and Singapore, further strengthening a strategic regional network designed to enhance speed, efficiency, and sustainability in biomanufacturing. In Singapore, the country’s expanded facility provides access to bench-to-pilot scale bioprocessing, expert-led training, and deep collaborations with Thermo Fisher’s technical teams to scale early-stage processes, supporting flexible and sustainable biomanufacturing.

Southeast Asia RNAi Technology Market Trends

This section discusses the key market trends that are influencing the various segments of the Southeast Asia RNAi Technology market, as found by our team of research experts.

Increased Government Support for Genomics

Genomics is rapidly becoming a strategic pillar of healthcare innovation and biopharmaceutical development for governments in Southeast Asia. The infrastructure of sequencing, bioinformatics, and molecular biology is being enhanced by public funding programs, national genomics initiatives, and research grants. This policy-led emphasis is contributing directly to the uptake of RNAi technologies as critical tools for analyzing gene function and validating targets. Translational research is also being accelerated by supportive regulations and public-private collaboration models. Further, long-term government support is likely to increase the application of RNAi to drug discovery and targeted medicine beyond the academic community.

Southeast Asia RNAi Technology Industry Segmentation

This section provides an analysis of the key trends in each segment of the Southeast Asia RNAi Technology market, along with forecasts at the country level for 2025-2033.

The siRNA (Short interfering RNA) market held the dominant share of the RNAi Technology market in 2024.

Based on type, the market is segmented into siRNA (Short interfering RNA), shRNA (Short hairpin RNA), miRNA (microRNA), and others. Among these, the siRNA (Short interfering RNA) market held the largest share in 2024. This is mainly because it is clinically proven, commercial-ready, and can be delivered through established delivery systems. Its established track record in rare diseases, oncology, and metabolic diseases enhances the level of confidence among pharma and biotech companies in Singapore-based innovation hubs. This directly drives increased demand for siRNA production, screening instruments, and translational research services in the region. For example, on October 2, 2025, Researchers from NUS Medicine developed a novel RNA-based therapy that could transform treatment for metabolic dysfunction-associated steatohepatitis (MASH), previously known as Non-alcoholic fatty liver disease (NAFLD), which affects approximately 25% of people worldwide, and up to 40% of adults in Singapore. The team created a tiny medicine made of lipid nanoparticles, fat-like particles that can safely deliver genetic drugs (siRNA) into liver cells. Once inside, the siRNA silences a gene called SPTLC2, which produces ceramides, a type of fat that drives liver fat build-up, inflammation, and fibrosis when the levels are elevated.

The pharmaceutical & biotechnology companies segment held the dominant share in the RNAi Technology market in 2024.

Based on the end-user, the market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, contract development & manufacturing organizations (CDMOs), and others. Among these, the pharmaceutical & biotechnology companies segment held the dominant share of the Southeast Asia RNAi Technology market in 2024. The pharmaceutical and biotechnology companies contribute to market growth by increasing investment in R&D, diversifying their pipelines, and outsourcing RNAi-based discovery efforts. These companies in Southeast Asia are increasingly using RNAi to de-risk drug targets before clinical investment, thereby enhancing development efficiency. Their inclination toward scalable, validated RNAi systems enhances long-term commercial adoption across the value chain. For example, on April 23, 2025, GenScript Biotech Corporation, a global leader in biotechnology research services, and NSG Bio, Singapore's premier biotech incubator, announced a strategic partnership designed to accelerate innovation and growth within the biotechnology sector. Through this partnership, GenScript will provide exclusive preferential rates along with technical guidance from experienced scientists across its extensive range of biotechnology services and products to NSG Bio residents.

Singapore held a dominant share of the Southeast Asian RNAi Technology market in 2024

Singapore is leading Southeast Asian RNAi technology because of its established biomedical ecosystem, strong IP protection, and a government that is proactive and supportive of advanced therapeutics. The availability of global life science companies, RNA and genomics research institutes, and translational medicine programs enhances the adoption of RNAi in discovery and early clinical stages. Time-to-market is also minimized by local supply of quality reagents, CDMO assistance, and talent. Moreover, Singapore is the key commercialization hub for RNAi technology in the region, serving as a regional headquarters and an innovative hub.

For example, on December 1, 2025, Precision Health Research, Singapore (PRECISE) announced a landmark partnership with companies Alnylam, Bayer, Boehringer Ingelheim, and Novo Nordisk, under Phase II of Singapore’s National Precision Medicine (NPM) programme. This pioneering initiative marks Singapore as the first country in Asia to establish a pre-competitive collaboration with leading pharmaceutical companies, contributing to a vibrant precision health ecosystem and reaffirming Singapore as a leading hub for precision medicine innovation in Asia.

Southeast Asia RNAi Technology Industry Competitive Landscape

The Southeast Asia RNAi Technology market is competitive, with several global and international market players. The key players are adopting various growth strategies to enhance their market presence, including partnerships, agreements, collaborations, new product launches, geographic expansions, and mergers and acquisitions.

Top Southeast Asia RNAi Technology Companies

Some of the major players in the market are GenScript, Integrated DNA Technologies, Inc. (Danaher Corporation), Thermo Fisher Scientific Inc., Merck KGaA, QIAGEN, Revvity, (OligoX) ABT Biomedical Solutions Co., Ltd., Bio Basic Asia Pacific Pte Ltd., and others.

Recent Developments in the Southeast Asia RNAi Technology Market

• On August 26, 2025, Hongene Biotech Corporation, a contract development and manufacturing organization (CDMO) specializing in nucleic acid therapeutics, entered a non-exclusive licensing agreement with the UMass Chan Medical School to produce and supply extended nucleic acid (exNA) monomers and exNA-modified oligonucleotides for research use. The agreement strengthens Hongene’s RNA chemistry portfolio and expands access to innovative oligonucleotide technologies for academic and biopharmaceutical researchers developing RNA interference (RNAi), antisense oligonucleotides (ASOs), CRISPR guides, and other oligo-based modalities.

• On April 23, 2025, GenScript Biotech Corporation, a global leader in biotechnology research services, and NSG Bio, Singapore's premier biotech incubator, announced a strategic partnership designed to accelerate innovation and growth within the biotechnology sector. Through this partnership, GenScript will provide exclusive preferential rates along with technical guidance from experienced scientists across its extensive range of biotechnology services and products to NSG Bio residents.

Southeast Asia RNAi Technology Market Report Coverage

Reasons to Buy the Southeast Asia RNAi Technology Market Report:

• The study includes market sizing and forecasting analysis confirmed by authenticated key industry experts.

• The report briefly reviews overall industry performance at a glance.

• The report covers an in-depth analysis of prominent industry peers, primarily focusing on key business financials, product portfolios, expansion strategies, and recent developments.

• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

• The study comprehensively covers the market across different segments.

Customization Options:

The Southeast Asia RNAi Technology Market can further be customized as per requirements or any other market segment. Besides this, UnivDatos understands that you may have your own business needs; hence, feel free to contact us to get a report that completely suits your requirements.